Jump to content
Prescribed BPC-157

The prescription dossier: gastric research, human reports and FDA documents.

BPC-157 references and regulatory documents

Original experiments, small human reports and reviews ask different questions. These are the records cited throughout the dossier.

Original experiments

For the gut question, start with Xue et al. on rat gastric ulcers. It has the route comparison and the ulcer-formation inhibition figures discussed on the gut page. The duodenocolic-fistula experiment moves to a different rat injury, while the anastomosis paper reviews healing of surgically joined bowel ends.

The transected rat Achilles study contains the biomechanical, functional and tissue findings that make the tendon record worth a close look. Hsieh et al. investigate the VEGFR2 vessel-growth mechanism in animal and cell models. He et al. provide the animal half-life and uptake measurements. These papers supply different parts of the case for further investigation.

Human reports and reviews

The knee-pain case series, bladder pilot and intravenous safety pilot make up the small human record described in the 2025 narrative review. Their study purposes and routes differ. The safety pilot is particularly easy to ask more of than its two participants can support.

I favour opening an original experiment beside a review that assesses its place in the literature. Reviews are useful for context and for identifying replication questions. A review gathering animal results still leaves those results in animals. Some records offer an abstract while the full article requires access; the publication details remain available below.

FDA compounding documents

The FDA bulk-substance page explains the ingredient requirements; the safety-risk page contains the withdrawn-nomination record and retained safety concerns. The advisory-committee agenda documents a proposed subject for discussion. The legal analysis addresses the January 2025 policy change.

The dates recorded with those sources belong to the source record.

Section 503A bulk substances

U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA, verified 2026-05-29.

Open document ›

FDA safety risks and withdrawn nominations

U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 Category 2 entry; effective with the September 29, 2023 nominated-substances update). FDA, page verified 2026-05-29.

Open document ›

Pharmacy Compounding Advisory Committee agenda

U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157, KPV, TB-500, and MOTs-C as bulk drug substances being considered for inclusion on the 503A Bulks List). FDA, verified 2026-05-29.

Open document ›

Interim compounding policy

U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page; guidance finalized January 2025). FDA, verified 2026-05-29.

Open document ›

Analysis of the January 2025 policy change

McDermott Will & Emery. End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists (legal analysis of the January 7, 2025 FDA action). Verified 2026-05-29.

Open document ›
  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. ↗
  6. Gojkovic S, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022;28(1):23-46. ↗
  7. Sikiric P, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. Life Sci. 1993;53(18):PL291-296. ↗
  8. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  9. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  10. Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  11. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol. 2024;75(1). ↗
  12. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats - A Review. Pharmaceuticals (Basel). 2024;17(8):1081. ↗
  13. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  14. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
  15. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1450. ↗
  16. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  17. Tohyama Y, et al.. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76:345-357. ↗
  18. Boban Blagaic A, et al.. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512:173-179. ↗
  19. Chang CH, et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. ↗